Read Article—Nicholas Jacobson, an associate professor of biomedical data science and psychiatry, is quoted in a story about the personalization of psychiatric care that features Therabot, AI-powered software developed in his lab that was the first therapy chatbot to undergo a clinical trial. “If you can monitor and predict ebbs and flows in symptoms, then you can deliver digital interventions at the right time,” Jacobson said.

Read article—Angelo Volandes, a professor of medicine, writes an opinion piece about keeping pace with AI technology in health care. “This fall, Geisel launched an AI curriculum that begins the moment students arrive, because we recognized a critical truth: If medical schools don’t guide how students think about and use these tools, technology companies will drive both the curriculum and clinical practice,” Volandes writes.

Read article—Nicholas Jacobson, an associate professor of biomedical data science and psychiatry, is cited in an article about OpenAI CEO Sam Altman’s claims that parenting without ChatGPT would be impossible. Jacobson notes that users poorly understand ChatGPT’s limitations.

Read article — Nicholas Jacobson, an associate professor of biomedical data science and psychiatry, and Michael Heinz, an assistant professor of psychiatry, are featured in a story about the status of AI therapy chatbots, with reference to their work on Therabot. “I think we’ve reached a level where we are close to matching human therapy in terms of both efficacy and safety,” Jacobson said.

Read article — A Perspective’s article in the NEJM by Geisel professors of medicine Angelo Volandes and Nathan Goldstein, and co-author Aretha Davis, highlights the opportunities and challenges of AI in rural healthcare.

Read Article — Nicholas Jacobson, an associate professor of biomedical data science and psychiatry, is quoted in an article about the Nov. 6 FDA advisory committee meeting on regulating AI chatbots for psychotherapy. “A product-centric approval process that could be too slow and can be rigid for the field could guarantee that a product that is approved would be obsolete by the time it’s really deployed,” said Jacobson, who told the committee about his work on Therabot, the first generative AI chatbot to undergo a clinical trial.

Read article – Michael Heinz, an assistant professor of psychiatry and research psychiatrist, and Nicholas Jacobson, an associate professor of biomedical data science and psychiatry, are featured in a story about the use of chatbots for psychotherapy, with mention of the Therabot platform developed at Dartmouth. “Ultimately these models are generative, and you can’t guarantee in any particular situation how it’s going to respond,” Heinz said. “I think that’s why we need human oversight.”

Read article – Thomas Thesen, an associate professor of medical education, is featured in an article about training faculty and administrators in medical schools on how to use AI, with a mention of the AI teaching academy for faculty that Thesen co-directs. “We have to teach people principles and critical thinking about AI,” Thesen said.

Read article – An article about the launch of Evergreen, an AI-driven platform designed by students and faculty to help students maintain well-being and manage stress. The article quotes Nicholas Jacobson, an associate professor of biomedical data science and psychiatry; Ayush Saran D ’27; and Teddy Roberts D ’26. “They’re being really careful that everything the chatbot is going to say is something they can say is evidence-backed, and we’re specifically cutting things if we can’t 100% say that the evidence supports this claim,” Roberts said. 

Listen to story – Michael Heinz, an assistant professor of psychiatry, talks to the In Good Health podcast about the use of AI in therapy and Dartmouth’s Therabot study. “Our goal is never to reduce the human connection that folks have, but I think there are a lot of people out there who either don’t have access to a therapist or are afraid to go see a therapist,” Heinz said.